The National Institute for Health & Clinical Excellence (NICE) have approved the usage of a new drug to treat skin cancer on the NHS.
Melanoma is the fifth most common cancer in the UK, and affects people of all ages and backgrounds.
New drug Pembrolizumab (trade name Keytruda) has been fast-tracked through approval checks in England via the Government’s Early Access to Medicines Scheme. The drug can both stall tumour growth and shrink existing cancers. It is a particularly helpful breakthrough, because it blocks biological pathways and stimulates the body’s immunity in fighting the disease.
More than 2,000 people in Britain die each year from skin cancer. In many instances, earlier detection and treatment of cancer would have led to a better prognosis or even a cure.
Our specialist team of medical negligence solicitors have dealt with many cases involving delayed diagnosis of melanoma, either due to a failure on the part of the GP to refer to hospital, or misinterpretation of test results and biopsies.
If you or a loved one have concerns regarding skin cancer diagnosis or treatment, contact Davies and Partners Solicitors for free initial advice and assistance on 01454 619 619.
Please also see our blog relating to a successful claim made by Davies and Partners' Medical Negligence team to fund the costs for a client for of new cancer drugs Ipilimumab and Nivolumab